Jeffery Testani, MD
Cardiovascular Disease · New Haven, CTNPI 1588729750
Payments from drug & device makers
Across 173 payments — averaging $19,592 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1.9M
- Merck$707K
- Sanofi US Services Inc.$443K
- Eli Lilly$100K
- Bayer$68K
- Boehringer Ingelheim International GmbH$46K
- plus $133K from 15 others
What the payments were for
- Consulting fees$319,95159%
- Speaking & faculty fees$182,59733%
- Travel & lodging$41,9178%
- Food & beverage$1,3470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 23 | $1,891,470 |
| Merck | 16 | $706,962 |
| Sanofi US Services Inc. | 20 | $443,431 |
| Eli Lilly | 24 | $100,317 |
| Bayer | 16 | $68,254 |
| Boehringer Ingelheim International GmbH | 22 | $46,085 |
| E.r. Squibb & Sons, L.L.C. | 5 | $40,410 |
| AstraZeneca | 14 | $23,326 |
| Bard Peripheral Vascular, Inc. | 9 | $22,913 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $22,718 |
| Terumo Medical Corporation | 2 | $7,875 |
| Regeneron | 3 | $4,680 |
| Boehringer Ingelheim Canada Ltd.ltee | 5 | $3,224 |
| Edwards Lifesciences | 4 | $3,079 |
| Vifor Pharma, Inc. | 1 | $2,500 |
| Medtronic | 2 | $1,013 |
| W. L. Gore & Associates, Inc. | 1 | $875 |
| Astrazeneca UK Limited | 1 | $129 |
| Impulse Dynamics (USA) Inc. | 1 | $80 |
| Abiomed | 1 | $36 |
| Abbott | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOTAGLIFLOZIN$184,219
- Non-Covered$47,155
- JARDIANCE$22,064
- FARXIGA$5,276
- Veltassa$2,500
- Product in Development$875
How this compares
$3,389,399 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in New Haven
- Harlan KrumholzNew Haven$4M
- Nihar DesaiNew Haven$3.2M
- John ForrestNew Haven$1.2M
- Hyung ChunNew Haven$1.1M
- Rohan KheraNew Haven$930K
- Carlos Mena-HurtadoNew Haven$665K
- John StendahlNew Haven$419K
- Tariq AhmadNew Haven$317K
- Rachel LampertNew Haven$310K
- Daniel JacobyNew Haven$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.